George Tidmarsh and Vinay Prasad have taken leadership roles at CDER and CBER, respectively, impacting FDA's drug and ...
The FDA announced that it removed a limitation on the use of real-world evidence (RWE) in drug and device application reviews ...
The FDA now accepts RWE for device submissions without needing identifiable patient data, facilitating the use of large, de-identified databases. This change addresses previous limitations that ...
The FDA is being transformed from an independent regulator into a high-stakes bargaining chip for White House deal-making.
Aldeyra submitted the single successful trial to the FDA over the summer and the agency accepted the resubmitted NDA for ...
Many Medtech startups view FDA and similar regulatory bodies as a roadblock. Something that is there to get in their way, slow them down, and cost them a fortune. Smart companies see regulations as an ...
A regulation with potentially major implications for the pharmaceutical industry has cleared its review, teeing it up for ...
An FDA panel of experts has called for a loosening of regulations and expanding access to testosterone replacement therapy.
"This risk is exacerbated by the fact that there is currently no proven, widely accepted standard to determine marijuana ...
Dr. Helen Bernie said on a Dec. 10 panel hosted by the U.S. Food and Drug Administration that serum testosterone "is one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback